![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » EU Finalizes Deal With J&J for 400 Million Doses of COVID-19 Vaccine
EU Finalizes Deal With J&J for 400 Million Doses of COVID-19 Vaccine
Johnson & Johnson has finalized a deal with the European Commission for 400 million doses of its COVID-19 vaccine candidate, Ad26.COV2.S.
Ad26.COV2.S is derived from a common cold virus that is modified to carry a gene from the SARS-CoV-2 virus, which causes the immune system to develop resistance to the coronavirus.
Dosing in a phase 3 trial of Ad26.COV2.S was recently suspended following a reported adverse event. The late-stage trial, which began in September, aims to enroll 60,000 participants across three continents to evaluate a single vaccine dose vs. placebo. — Jason Scott
Upcoming Events
-
21Oct